Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Warning

There is a more recent version of this eprint available. Click here to view it.

Moreau, P, van de Donk, NWCJ, Miguel, JS et al. (17 more authors) (2016) Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs, 76 (8). pp. 853-867. ISSN 0012-6667

Abstract

Metadata

Item Type: Article
Authors/Creators:
  • Moreau, P
  • van de Donk, NWCJ
  • Miguel, JS
  • Lokhorst, H
  • Nahi, H
  • Ben-Yehuda, D
  • Cavo, M
  • Cook, G
  • Delforge, M
  • Einsele, H
  • Zweegman, S
  • Ludwig, H
  • Driessen, C
  • Palumbo, A
  • Facon, T
  • Plesner, T
  • Dimopoulos, M
  • Sondergeld, P
  • Sonneveld, P
  • Mateos, M-V
Dates:
  • Published: May 2016
  • Published (online): 25 April 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Oncology and Clinical Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 21 Dec 2016 10:20
Last Modified: 21 Dec 2016 10:20
Published Version: http://doi.org/10.1007/s40265-016-0573-4
Status: Published
Publisher: Springer
Identification Number: 10.1007/s40265-016-0573-4
Related URLs:
Open Archives Initiative ID (OAI ID):

Available Versions of this Item

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics